EN DE
STOCK COMPARISON

Bachem Holding vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Bachem Holding (BANB) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Bachem Holding trades at CHF 77.10 versus a fair value of CHF 27.72 (-64%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).
Bachem Holding
BANB.SW · CHF · Materials
-64%
upside to fair value
overvalued
PriceCHF 77.10
Fair ValueCHF 27.72
Quality56/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$558
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Bachem HoldingVertex Pharmaceuticals
Valuation
35.9×P/E (TTM)28.8×
9.47×P/S (TTM)10.06×
4.51×P/B6.59×
31.1×EV/EBITDA23.8×
0.61×PEG1.72×
−64.0%Fair value upside−50.0%
0.6%Dividend yield0.1%
CHF 0.45Dividend per share—
Profitability
26%Operating margin38%
0.91×EBIT margin trend (5Y)0.86×
10%Return on equity24%
5%Return on assets12%
Growth
5%Revenue growth (YoY)8%
9.3%Avg. growth/yr (3Y)10.6%
11.6%Avg. growth/yr (5Y)14.2%
+12.8%Value creation/yr+13.6%
Balance & size
310.5×Interest coverage (EBIT/interest)357.9×
—Debt / equity0.03×
$7BMarket cap$123B
expensiveGrowth qualityhealthy
Valuation multiples (P/E, P/S, P/B, EV/EBITDA) are shown but not scored here: the two companies sit in different sectors, and multiples only compare fairly between similar business models. PEG stays scored, as it relates the P/E to growth.

Vertex Pharmaceuticals leads: 3 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Bachem Holdingof which business quality 56 · market factors 66 Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
43
72
Quality GrowthAre margins and returns improving?
49
65
CashflowEarnings quality: real cash, not paper profit
47
79
Fin. StrengthBalance sheet, leverage, solvency risk
81
92
InvestmentDisciplined investing over empire-building
29
58
Low VolatilityCalm price path (market factor)
61
85
MomentumPrice trend over the last 3–12 months (market factor)
67
70
52W MomentumDistance to the 52-week high (market factor)
72
89
Net IssuanceBuybacks instead of dilution
79
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyBachem HoldingPrice CHF 77.10Vertex PharmaceuticalsPrice $558
DCF Modelsn/a-19%below the price$453
Earnings-Based-75%below the priceCHF 18.98-8%close to the price$516
Dividend Discount-91%below the priceCHF 6.69-99%below the price$7.07
Multiples-65%below the priceCHF 27.12-50%below the price$278
Asset-Based-83%below the priceCHF 13.04-91%below the price$49.27
Growth DCFn/a-38%below the price$348
Economic Profit-75%below the priceCHF 19.09-54%below the price$254
Growth Earnings-62%below the priceCHF 29.38+24%above the price$692
Minimum-91%below the priceCHF 6.69-99%below the price$7.07
Maximum-62%below the priceCHF 29.38+24%above the price$692
Median-75%below the priceCHF 19.04-44%below the price$313
Geometric mean-78%below the priceCHF 17.12-67%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Bachem Holding: 16 of 16 models see the stock below the current price.

Vertex Pharmaceuticals: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Bachem Holding
Bear CHF 20.56Fair Value CHF 27.72Bull CHF 34.74
CHF 77.10 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$558 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Bachem Holding · Materials

Quality score56 · above median
Fair value upside-64% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Bachem Holding trades at CHF 77.10 versus a fair value of CHF 27.72 (-64%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Bachem Holding · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Bachem Holding

Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs PDD Holdings

Related to Vertex Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.